1. Indonesia Stocks

  2. •

    Health services

  3. •

    Hospital/Nursing management
PT Sarana Meditama Metropolitan Tbk

PT Sarana Meditama Metropolitan Tbk

IIDX:SAME
276.00
IDR
+2.00
(+0.73%)
0.94EPS
960.96P/E
6.08TMarket Cap
PT Sarana Meditama Metropolitan Tbk
IDX:SAME
(Indonesia Stock Exchange)

Recent

price

276.00

P/E

ratio

960.96

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
IDR
29.83
37.28
45.71
56.82
70.05
85.55
105.02
58.39
122.44
93.89
81.35
89.38
99.51
108.52
111.81
Revenue per Share
2.57
5.17
6.37
6.24
1.63
7.94
6.5
-12.62
-28.13
10.64
0.25
0.71
0.69
1.75
0.37
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
0.91
0.91
0.39
1.11
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2.12
14.8
21.17
81.76
93.87
114.97
146.28
170.28
151.13
224.12
211.5
212.16
220.47
221.57
222.9
Book Value per Share
2.12
14.8
21.17
81.76
93.87
114.97
146.28
151.62
132.47
197.05
180.85
179.52
187.93
190
191.86
Tangible Book Value per Share
9,066
9,027
9,066
9,066
9,066
9,066
9,066
9,066
6,671
13,544
17,130
17,137
17,147
17,157
17,161
Basic Weighted Avg Shares
270,468
336,511
414,415
515,095
635,021
775,567
952,082
529,320
816,816
1,271,584
1,393,542
1,531,660
1,706,381
1,861,972
1,918,718
Sales/Revenue/Turnover
18.12
21.56
21.76
21.39
13.19
19.99
17.79
0.96
-1.1
16.09
2.04
2.06
5.46
6.17
4.86
Operating Margin (%)
13,619
13,628
18,365
19,335
40,961
39,384
50,197
46,606
45,910
69,776
98,180
88,176
73,768
76,025
78,426
Depreciation Expense
23,269
46,649
57,708
56,605
14,795
72,015
58,883
-114,385
-187,643
144,169
4,347
12,252
11,849
30,076
6,322
Net Income, GAAP
16.98
8.39
11.3
17.08
45.63
25.46
27.93
- -
- -
0.98
44.37
- -
46.02
36.82
49.36
Effective Tax Rate (%)
8.6
13.86
13.93
10.99
2.33
9.29
6.18
-21.61
-22.97
11.34
0.31
0.8
0.69
1.62
0.33
Profit Margin (%)
-95,629
-76,093
35,074
128,613
-11,207
38,549
305,789
-59,066
-128,856
527,250
195,012
-69,479
-171,955
-446,692
-703,531
Working Capital
119,953
101,840
165,140
315,302
435,931
441,055
979,123
985,704
1,011,640
20,937
648,318
682,768
595,763
389,376
471
LT Debt
19,223
134,174
191,961
741,180
850,973
1,042,284
1,326,091
1,683,434
1,537,845
4,442,987
3,983,018
3,983,619
4,138,250
4,165,748
4,199,941
Total Equity
- -
17.06
23.39
13.2
5.21
8.1
6.45
- -
- -
5.08
0.41
- -
1.1
1.42
0.9
Return on Invested Capital (%)
- -
24.56
23.1
9.71
3.17
7.8
5.7
- -
- -
5.24
0.47
- -
0.91
1.32
0.62
Return on Capital (%)
- -
60.82
35.39
12.13
1.86
7.61
4.97
-7.97
-12.88
5.54
0.12
0.34
0.32
0.79
0.17
Return on Common Equity (%)

Capital Structure

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
588,790
682,556
897,576
LT Borrowings
388,933
271,545
- -
LT Finance Leases
443
457
471
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17,156
17,165
17,165
Market Capitalization
6,210,429
5,870,304
6,076,280

Working Capital

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
506,795
544,314
514,895
Cash, Cash Equivalents & STI
152,450
174,196
128,062
Accounts Receivable, Net
259,347
252,926
275,196
Inventories
54,350
53,689
51,076
Total Current Liabilities
953,487
1,004,409
1,218,426
Payables & Accruals
- -
- -
- -
ST Debt
588,790
682,556
897,576
Deferred Revenue
- -
- -
- -

Growth Rates

IDR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
26.59%
36.62%
0.66%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
12.3%
11.71%
153.83%
Sales/Revenue/Turnover
17.38%
19.14%
9.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
433,160
411,894
433,644
425,070
1,706,381
2025
440,866
434,156
- -
494,682
1,861,972
2026
479,094
510,786
- -
- -
- -

Quarterly Earnings Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
-0.38
0.09
0.89
0.69
2025
0.56
0.28
- -
-0.16
1.75
2026
-0.05
0.3
- -
- -
- -

Quarterly Dividends Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Apollo Hospitals Enterprise Limited (NSE:APOLLOHOSP)
Max Healthcare Institute Ltd (NSE:MAXHEALTH)
Fortis Healthcare Ltd. (NSE:FORTIS)
Bangkok Dusit Medical Services Public Co. Ltd. (SET:BDMS)
Yatharth Hospital and Trauma Care Services Limited (NSE:YATHARTH)
HCA Healthcare, Inc. (NYSE:HCA)
Business
PT Sarana Meditama Metropolitan Tbk is an Indonesia-based healthcare company primarily engaged in providing healthcare services through the ownership, management, and operation of hospitals under the EMC Healthcare brand. The company offers a network of hospitals including EMC Alam Sutera, EMC Cibitung, EMC Cikarang, EMC Pekayon, EMC Pulomas, EMC Tangerang, and EMC Sentul, as well as specialty centers focusing on cardiovascular, digestive and bariatric, fertility, and laparoscopy care. It also operates additional hospitals such as Grha Kedoya Hospital and Grha MM2100 Hospital through its subsidiary PT Kedoya Adyaraya Tbk. Beyond hospital management, the company is involved in trading medical equipment, healthcare pharmacy services, real estate, and agriculture. Founded in 1984 and headquartered in Jakarta, PT Sarana Meditama Metropolitan Tbk serves patients across Indonesia with a focus on improving patient experience and expanding healthcare access. Recent major changes include the acquisition of the healthcare chain previously known as Omni Hospitals, rebranded as EMC Healthcare following its acquisition by the Emtek Group in 2021. The company has continued to expand its hospital network to eight hospitals by 2024, focusing on patient-centered care and medical excellence. PT Sarana Meditama Metropolitan Tbk has embraced technological advancements, adopting electronic medical record systems to enhance service quality and operational efficiency. The company operates primarily within the Indonesian market, notably in Jakarta, Banten, and West Java regions, adapting to evolving healthcare demands and maintaining strategic initiatives to enhance healthcare service delivery and infrastructure development.